The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.25
Bid: 35.00
Ask: 35.50
Change: -0.50 (-1.40%)
Spread: 0.50 (1.429%)
Open: 35.75
High: 35.75
Low: 35.25
Prev. Close: 35.75
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disposal

18 Jan 2010 07:00

RNS Number : 6804F
China Real Estate Opportunities PLC
18 January 2010
 



China Real Estate Opportunities plc

Disposal of Tangdao Bay investment at 10.9% premium to independent valuation

China Real Estate Opportunities plc ("CREO" or the "Company"), an AIM listed property company with an established investment and development property portfolio in China, today announces that it has executed an unconditional contract to dispose of its 50% interest in the Tangdao Bay joint venture development. 

CREO's 50% interest in the joint venture has been sold to its partner in the project, SIIC Shanghai Holdings Company ("SIIC"). The sale price was based on a property value of RMB1.389bn representing a 10.9% premium to the most recent independent valuation in June 2009. Net cash proceeds from the transaction amount to £33.8 million at today's exchange rates with no borrowings to be repaid from the sale proceeds and will be received upon the completion of the standard PRC regulatory procedures for the offshore repatriation of proceeds of domestic asset sales.

The sale price reinforces CREO's reported NAV, and follows on from the June 2009 disposal of CREO's interest in the City Centre 5 development at an 8.9% premium to the independent valuation of 31 December 2008.

Furthermore the Company announces that due to the contracted disposal of Tangdao Bay, it has decided not to proceed with the issuance of zero dividend preference shares. In November 2009 the Company announced it was considering such an issuance to facilitate the repurchase of the Company's own ordinary shares which are trading at a significant discount to net asset value. Accordingly the Company proposes to commit up to £15 million from its cash resources to fund a tender offer for its own shares upon receipt of the Tangdao Bay sale proceeds.

At the same time the Company continues to work with its advisers to generate third party demand for its shares.

Commenting, Ray HorneyCREO Chairman said: "The CREO Board is very pleased to announce the execution of an unconditional contract for the disposal of its 50% ownership of the Tangdao Bay development, reinforcing the strength of CREO's balance sheet and underpinning its published net asset value as this sale represents the second asset disposal in the past 6 months above independent valuation. This transaction reinforces the Company's strategy of focussing on its core investment and development assets, particularly in Shanghai, and will further strengthen the Company's cash position and provide a strong platform for the Company to move forward in 2010 and beyond." 

"This sale is timely and as such it is appropriate for the Company to cancel the zero dividend preference share issue and propose the allocation of a prudent sum from its own cash reserves to underwrite its earlier commitment to a repurchase of the Company's own shares."

ENDS

Contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0)1273 775225

Sarah Moriarty, Investor Relations 

Tel: +353 1 6189455

Matrix Corporate CapitalPaul Fincham, Rob Naylor Tel +44 (0)20 3206 7175

Davy

Des Carville

Tel: +353 1 679 6363

Citigate Dewe Rogerson Limited

Tom Baldock

Tel: + 44 (0) 20 7638 9571

Murray Consultants

Ed Micheau

Tel: + 3531 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISDBGDBISBBGGR
Date   Source Headline
21st Feb 202310:29 amRNSHolding(s) in Company
17th Feb 20232:05 pmRNSSecond Price Monitoring Extn
17th Feb 20232:00 pmRNSPrice Monitoring Extension
17th Feb 202312:10 pmRNSLaunch of Open Offer and Posting of Circular
16th Feb 20236:04 pmRNSResult of Placing and Subscription
16th Feb 20239:05 amRNSSecond Price Monitoring Extn
16th Feb 20239:00 amRNSPrice Monitoring Extension
16th Feb 20237:00 amRNSPlacing and Subscription to raise a minimum £25m
15th Feb 202311:05 amRNSSecond Price Monitoring Extn
15th Feb 202311:00 amRNSPrice Monitoring Extension
30th Jan 20238:51 amRNSAward of Shares under Share Incentive Plan
23rd Jan 202311:47 amEQSCreo Medical (CREO): Progressing on all fronts
18th Jan 20232:05 pmRNSSecond Price Monitoring Extn
18th Jan 20232:00 pmRNSPrice Monitoring Extension
11th Jan 20237:00 amRNSFY 2022 Trading Update
16th Dec 20222:05 pmRNSSecond Price Monitoring Extn
16th Dec 20222:00 pmRNSPrice Monitoring Extension
1st Dec 20222:12 pmRNSHolding(s) in Company
24th Oct 20227:00 amRNSKamaptive Licence and Royalty Agreement with CMR
30th Sep 20227:00 amRNSTotal Voting Rights
23rd Sep 20227:00 amRNSExercise of Options
23rd Sep 20227:00 amRNSExercise of Options
22nd Sep 20227:00 amRNSChris Hancock elected as a Fellow of Royal Academy
9th Sep 20227:00 amRNSHalf-year Report
5th Sep 20227:00 amRNSNotice of Results
31st Aug 20227:00 amRNSTotal Voting Rights
8th Aug 20227:00 amRNSLTIP Awards and PDMR Dealing
4th Aug 20227:00 amRNSExercise of Options
3rd Aug 20227:00 amRNSH1 2022 Trading Update
2nd Aug 20227:00 amRNSAward of Shares under Share Incentive Plan
28th Jun 202212:33 pmRNSResult of AGM
28th Jun 20227:00 amRNSAGM Statement
27th May 20227:00 amRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSPosting of 2021 Annual Report and Accounts
23rd May 20227:01 amRNSFinal Results
23rd May 20227:00 amRNSCollaboration agreement with Intuitive
18th May 20223:22 pmRNSHolding(s) in Company
17th May 20227:00 amRNSNotice of Results
28th Apr 20227:00 amRNSTrading update and notice of results
20th Apr 20227:00 amRNSOpening of Singapore regional hub
5th Apr 20227:00 amRNSCTO wins Technology Innovator of the Year Award
16th Mar 20227:00 amRNSAlbyn Medical earn out update
28th Feb 20227:00 amRNSTotal Voting Rights
7th Feb 20227:00 amRNSPresentation at Growth and Innovation Forum 2022
4th Feb 20227:00 amRNSAward of Shares under Share Incentive Plan
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSTrading update
24th Jan 20227:00 amRNSLicensing & Partnership update
31st Dec 20217:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.